INTRODUCTION
• Health-related quality of life (HRQoL) is an important endpoint in studies of outcomes in oncology.
Patients' own rating of their health or symptom burden, obtained via a variety of HRQoL or symptom measures, is predictive of overall survival (OS) or progression-free survival (PFS). [1] [2] [3] [4] [5] • The importance of assessing HRQoL in patients with advanced prostate cancer is increasingly recognized, and the Prostate Cancer Clinical Trials Working Group 3 acknowledges the need to evaluate the strength of association between early changes in individual outcomes, including patient-reported outcomes (PROs), and later events such as PFS and/or OS in castration-resistant prostate cancer (CRPC). 6 • Although improved HRQoL has been linked to better clinical outcomes in metastatic CRPC (mCRPC), 7 data on the relationship between radiographic PFS (rPFS) or OS and HRQoL in mCRPC is sparse.
• The PREVAIL trial (NCT01212991) showed that the androgen receptor inhibitor enzalutamide delayed radiographic disease progression or death, delayed deterioration in HRQoL, and improved OS vs placebo in chemotherapy-naïve men with mCRPC. 8 PREVAIL provides a platform for better understanding of the relationship between HRQoL and traditional clinical outcome measures.
OBJECTIVE
• To investigate the association between HRQoL (at baseline and time-dependent longitudinal change) and rPFS and OS in PREVAIL.
METHODS
• PREVAIL was a double-blind, phase 3 trial in asymptomatic/mildly symptomatic chemotherapynaïve patients with mCRPC randomized to enzalutamide 160 mg/day (n = 872) or placebo (n = 845). 8 • HRQoL was assessed using Functional Assessment of Cancer Therapy-Prostate (FACT-P) version 4, a 39-item instrument validated for mCRPC. [9] [10] [11] In addition to FACT-P total score, the following 3 subdomains were assessed: physical wellbeing (PWB), functional wellbeing (FWB), and prostate cancer subscale (PCS).
• HRQoL data were collected at baseline, week 5, and week 13, then every subsequent 12 weeks until study drug discontinuation.
• The cutoff date for inclusion of PREVAIL data in these analyses was Sept 16, 2013 (interim OS analysis cutoff date).
Statistical Analyses
• First, demographic, clinical, and quality-of-life (QoL) variables were evaluated in a univariate analysis to determine which parameters showed individual prognostic value for rPFS or OS.
• In the multivariate analyses, the joint prognostic significance of all demographic, clinical, and baseline QoL or time-dependent QoL variables were investigated. All QoL covariates were retained in the model, but only the significant (using a significance level of 0.05) demographic and clinical variables were retained. Two different models were fit: one for the FACT-P total score and another for the subdomains, which were all introduced in a single model.
• Cox proportional hazard models with baseline (ie, fixed) or time-dependent covariates were fitted to time-to-event data (separately for OS and rPFS) to test whether baseline QoL scores or change in QoL scores predict rPFS or OS.
• Hazard ratio (HR) with associated 95% confidence interval (CI) for each QoL variable was the key measure and was calculated as the hazard of PFS/survival per the minimal clinically important difference (MCID) of the QoL variable. The following previously established MCID scores were used: 10 for FACT-P and 3 for PWB, FWB, and PCS. 10, [12] [13] [14] • Data were analyzed using SAS version 9.2 (SAS Institute, Cary, NC) and P values < 0.05 were judged to be nominally significant without multiplicity adjustment.
RESULTS

Demographic and Baseline Clinical Factors
• In the univariate analysis of demographic and baseline clinical factors, the following variables were predictive of rPFS: treatment group, presence of visceral disease at baseline, bone metastases at screening, and type of disease progression at study entry. Variables predictive of OS were treatment group, time since diagnosis, Eastern Cooperative Oncology Group Performance Status (ECOG PS) at baseline, pain at baseline, presence of visceral disease at baseline, bone metastases at screening, and type of disease progression at study entry ( Table 1) . 
Baseline HRQoL
• In the univariate analysis investigating QoL baseline measurements, all 4 of the FACT-P scores were predictive of rPFS and OS ( Table 1) . In general, every MCID point difference in baseline QoL score (ie, higher score indicates better QoL) was associated with a significant decrease in the risk of radiographic progression (HR, 0.91 to 0.95; P < 0.05) or death (HR, 0.76 to 0.88; P < 0.001).
• In the multivariate analyses, after adjusting for prespecified covariates that were statistically significant in the univariate analysis, baseline QoL variables lost their significance with regard to rPFS (Figure 1) . For OS, only FWB lost its significance. Every 3-point difference (ie, 3 points higher in baseline score indicates better QoL) in the baseline PWB and PCS was associated with a 15% and 11% decreased risk of death (HR [ 
Time-Dependent Longitudinal Change in QoL Score
• In the multivariate analysis, increases in FACT-P total score and PWB score were significantly associated with rPFS (HR, 0.93 and 0.91, respectively) (Figure 2 ). For OS, statistically significant associations were observed for all 4 FACT-P scores. Thus, every 3-point increase (improvement) at subsequent assessments compared with baseline assessment in PWB, FWB, or PCS was associated with a 12%, 10%, and 10% decreased risk of death (HR [ 
CONCLUSIONS
• In the PREVAIL study, baseline HRQoL was an independent prognostic factor for rPFS and OS in mCRPC.
• In general, point estimates for the HRs were smaller in the time-dependent model, revealing a stronger association between changes in QoL throughout the study and survival outcomes compared with the simpler model, including baseline QoL score only.
• This exploratory study provides preliminary evidence indicating that patients with mCRPC whose PWB, FWB, PCS, and FACT-P scores improve during treatment have a significantly increased probability of survival.
• The observed associations between QoL scores and clinical outcomes may have the potential to influence clinicians' treatment approaches for mCRPC in the future. However, additional studies are required to validate these observations and to demonstrate that therapy selection based on these variables helps patients.
